Orthobond Secures De Novo Classification Grant for First-in-Class Antibacterial Surface Treatment Applied to a Spinal Device
Orthobond Corporation , a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, announced today that the U.S. Food and Drug Administration (FDA) granted its De Novo marketing request for the use of Ostaguard™, its proprietary antibacterial surface treatment, on a permanent medical device.